Lyon Street Capital LLC bought a new position in shares of BioTelemetry, Inc. (NASDAQ:BEAT) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,352 shares of the medical research company’s stock, valued at approximately $507,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Teachers Advisors LLC lifted its position in BioTelemetry by 7.6% in the first quarter. Teachers Advisors LLC now owns 46,786 shares of the medical research company’s stock valued at $1,354,000 after purchasing an additional 3,297 shares during the period. Vanguard Group Inc. lifted its position in BioTelemetry by 11.7% in the first quarter. Vanguard Group Inc. now owns 1,674,580 shares of the medical research company’s stock valued at $48,480,000 after purchasing an additional 174,844 shares during the period. Morgan Stanley lifted its position in BioTelemetry by 6.3% in the first quarter. Morgan Stanley now owns 160,392 shares of the medical research company’s stock valued at $4,644,000 after purchasing an additional 9,546 shares during the period. Schwab Charles Investment Management Inc. lifted its position in BioTelemetry by 6.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 125,770 shares of the medical research company’s stock valued at $3,642,000 after purchasing an additional 7,140 shares during the period. Finally, State Street Corp lifted its position in BioTelemetry by 4.6% in the first quarter. State Street Corp now owns 737,798 shares of the medical research company’s stock valued at $21,356,000 after purchasing an additional 32,124 shares during the period. Institutional investors and hedge funds own 82.23% of the company’s stock.
BioTelemetry, Inc. (BEAT) opened at $26.80 on Thursday. BioTelemetry, Inc. has a 1-year low of $20.00 and a 1-year high of $39.20. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.60 and a quick ratio of 1.48. The stock has a market cap of $870.16, a PE ratio of 36.78, a price-to-earnings-growth ratio of 1.68 and a beta of 0.53.
BEAT has been the subject of a number of recent analyst reports. Off Wall Street initiated coverage on shares of BioTelemetry in a research report on Friday, September 15th. They issued a “sell” rating for the company. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. SunTrust Banks initiated coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 target price for the company. Dougherty & Co reaffirmed a “buy” rating and issued a $40.00 target price on shares of BioTelemetry in a report on Wednesday, November 8th. Finally, Raymond James Financial initiated coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. BioTelemetry presently has an average rating of “Buy” and a consensus target price of $42.86.
TRADEMARK VIOLATION WARNING: “15,352 Shares in BioTelemetry, Inc. (BEAT) Acquired by Lyon Street Capital LLC” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/07/15352-shares-in-biotelemetry-inc-beat-acquired-by-lyon-street-capital-llc.html.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry, Inc. (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.